1. Medtech Insight

Intuitive Still Dominates, But New Robotic Surgery Players Could Speed Penetration

Intuitive Surgical's latest earnings and procedure numbers beat analysts' expectations and further solidified its leading position in surgical robotics. But potential robotic rivals are in the wings with alternative solutions that could make robotic surgery more affordable and accessible, including Cambridge Medical Robotics, Transenterix, Titan Medical, SOFAR and J&J/Google.

Intuitive Surgical Inc. in July further consolidated its leading position in the surgical robotics market with a second quarter performance that beat analysts’ expectations on all key measures, including growth in procedure volume and capital sales.

The company reported that the number of da Vinci systems – the company’s flagship robotic technology for performing laparoscopic surgery – placed during the quarter jumped 23% from 96 units...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.